Physician profile
John Patrick Paraskos
NPI 1336181379
$3,538.92
in general payments reported to CMS, 2019-2025
47 companies · $509 in 2025
The $509 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $152 · 2021: $768 · 2022: $603 · 2023: $726 · 2024: $478 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,713.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $610.70 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $217.26 | 2021-2025 | |
| Minerva Surgical, INC | $214.89 | 2019-2025 | |
| Hologic Sales and Service, LLC | $200.33 | 2019-2025 | Myosure Tissue Removal Device, Novasure, Coolseal Generator |
| Daiichi Sankyo INC. | $178.89 | 2019-2024 | Injectafer |
| Astellas Pharma US INC | $175.92 | 2022-2025 | Veozah, Myrbetriq |
| Gynesonics, INC. | $168.78 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Therapeuticsmd, INC. | $152.76 | 2019-2022 | |
| Exeltis, USA INC. | $149.22 | 2021-2024 | Slynd |
| Channel Medsystems, INC. | $134.40 | 2022-2023 | |
| Coopersurgical, INC. | $95.33 | 2019-2024 | Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $83.46 | 2019-2024 | |
| Aspira Women'S Health INC | $79.95 | 2021-2024 | Ova1 |
| Evofem Biosciences, INC. | $76.47 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $74.88 | 2021 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $71.66 | 2021-2024 | Twirla |
| Shield Therapeutics INC | $68.53 | 2022-2025 | Accrufer |
| Biogen, INC. | $67.26 | 2024-2025 | Zurzuvae |
| Amgen INC. | $65.20 | 2023-2025 | Evenity, Prolia, Prolia |
| Organon LLC | $61.30 | 2022-2025 | Jada System, Nexplanon |
| Myriad Women'S Health, INC. | $54.70 | 2023 | Myrisk |
| Pfizer INC. | $54.33 | 2022-2023 | |
| Vertical Pharmaceuticals, LLC | $34.61 | 2019-2020 | |
| Alydia Health | $31.36 | 2021 | |
| Merck Sharp & Dohme LLC | $31.24 | 2021-2024 | Gardasil 9, Gardasil |
| Optumhealth Care Solutions, LLC | $27.60 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Dysis Medical, INC. | $26.70 | 2023 | Dysis Ultra 2.0, Dysis V3 Digital Coploscope, Dysis View |
| Exact Sciences Corporation | $24.65 | 2024 | Cologuard Collection Kit |
| Amag Pharmaceuticals, INC. | $23.65 | 2019 | |
| Mylan Pharmaceuticals INC. | $22.20 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $22.00 | 2022 | |
| Baxter Healthcare | $20.38 | 2025 | Tisseel |
| Meditrina | $19.32 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $18.67 | 2023 | Exparel |
| Duchesnay USA Incorporated | $18.65 | 2019 | |
| Axsome Therapeutics, INC. | $18.35 | 2025 | Auvelity |
| Ethicon US, LLC | $18.00 | 2023 | |
| Becton, Dickinson and Company | $17.23 | 2024 | Bd Onclarity |
| Scynexis, INC. | $16.82 | 2022 | |
| Boston Scientific Corporation | $15.85 | 2020 | |
| Sumitomo Pharma America, INC. | $14.98 | 2023 | Gemtesa |
| Lilly USA, LLC | $13.53 | 2025 | Zepbound |
| Allergan, INC. | $12.43 | 2020 | |
| Avion Pharmaceuticals | $11.72 | 2019 | |
| Ascend Therapeutics US, LLC | $11.56 | 2021 | |
| Coloplast Corp | $11.20 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Paraskos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.